- Home
- AQMS vs CLDI Comparison
AQMS vs CLDI Comparison
Compare AQMS & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- CLDI
- Stock Information
- Founded
- AQMS 2014
- CLDI 2014
- Country
- AQMS United States
- CLDI United States
- Employees
- AQMS N/A
- CLDI N/A
- Industry
- AQMS Metal Fabrications
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AQMS Industrials
- CLDI Health Care
- Exchange
- AQMS Nasdaq
- CLDI Nasdaq
- Market Cap
- AQMS 13.7M
- CLDI 14.0M
- IPO Year
- AQMS 2015
- CLDI N/A
- Fundamental
- Price
- AQMS $1.52
- CLDI $0.47
- Analyst Decision
- AQMS Strong Buy
- CLDI Strong Buy
- Analyst Count
- AQMS 3
- CLDI 2
- Target Price
- AQMS $21.00
- CLDI $15.00
- AVG Volume (30 Days)
- AQMS 73.8K
- CLDI 386.9K
- Earning Date
- AQMS 05-14-2025
- CLDI 05-13-2025
- Dividend Yield
- AQMS N/A
- CLDI N/A
- EPS Growth
- AQMS N/A
- CLDI N/A
- EPS
- AQMS N/A
- CLDI N/A
- Revenue
- AQMS N/A
- CLDI N/A
- Revenue This Year
- AQMS N/A
- CLDI N/A
- Revenue Next Year
- AQMS $550.00
- CLDI N/A
- P/E Ratio
- AQMS N/A
- CLDI N/A
- Revenue Growth
- AQMS N/A
- CLDI N/A
- 52 Week Low
- AQMS $1.33
- CLDI $0.35
- 52 Week High
- AQMS $11.40
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- AQMS 36.08
- CLDI 39.82
- Support Level
- AQMS $1.42
- CLDI $0.41
- Resistance Level
- AQMS $1.54
- CLDI $0.52
- Average True Range (ATR)
- AQMS 0.16
- CLDI 0.07
- MACD
- AQMS -0.01
- CLDI 0.02
- Stochastic Oscillator
- AQMS 11.11
- CLDI 69.70
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.